News

Experimental drugs under EMA scrutiny
Enlarge image

EbolaEUFrance

Experimental drugs under EMA scrutiny

30.09.2014 - In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

With 2,600 people dead and the infection rate gathering speed, the current Ebola outbreak represents the widest geographical spread of the disease ever reported. Although there is currently neither vaccine nor cure available, there are several drugs under development. In desperation, local health authorities have already used these experimental compounds to treat patients, in the hope that they might prove effective.

In an effort to support medical staff on-site, the European Medicines Agency is now starting an investigation of these early stage drugs. “Health authorities or practitioners who need to take a decision whether or not to use an experimental Ebola treatment in a patient are currently lacking independent information,” explains Guido Rasi, Executive Director of the EMA. “I have therefore asked the EMA Committee for Medicinal Products for Human Use, CHMP, to scrutinise all the available information about experimental treatments and compile everything we know to date about their efficacy, safety and quality. This will facilitate evidence-based decision-making.”

The EMA has now called together a group of specialists from all over Europe – experts in vaccines, infectious diseases and clinical trial design. The group has contacted companies known to be developing potential treatments, among them French immunotherapy specialist Fab'entech and US companies Biocryst and Sarepta. Companies that have not yet been contacted are invited to send available data about their treatments under development to the EMA for a review. Meanwhile, human trials for Glaxosmithkline's Ebola vaccine are being put on the fast track with the help of an international consortium.



© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2014-03/experimental-ebola-drugs-under-ema-scrutiny.html

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=84e81f78a2ff57fea5f72d810e48c349&sort=asc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014